Related Experiment Video
Updated: Aug 9, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
A cell-penetrating antibody inhibits human RAD51 via direct binding
Audrey Turchick1, Denise C Hegan2, Ryan B Jensen2,3
1Department of Genetics, Yale University School of Medicine, New Haven, CT 06510, USA.
Abstract:
RAD51, a key factor in homology-directed repair (HDR), has long been considered an attractive target for cancer therapy, but few specific inhibitors have been found. A cell-penetrating, anti-DNA, lupus autoantibody, 3E10, was previously shown to inhibit HDR, sensitize tumors to radiation, and mediate synthetic lethal killing of BRCA2-deficient cancer cells, effects that were initially attributed to its affinity for DNA. However, as the molecular basis for its ability to inhibit DNA repair, we report that 3E10 directly binds to the N-terminus of RAD51, sequesters RAD51 in the cytoplasm, and impedes RAD51 binding to DNA. Further, we generate separation-of-function mutations in the complementarity-determining regions of 3E10 revealing that inhibition of HDR tracks with binding to RAD51 but not to DNA, whereas cell penetration is linked to DNA binding. The consequences of these mutations on putative 3E10 interactions with RAD51 and DNA are correlated with in silico molecular modeling. Taken together, the results identify 3E10 as a novel inhibitor of RAD51 by direct binding, accounting for its ability to suppress HDR and providing the molecular basis to guide pre-clinical development of 3E10 as an anti-cancer agent.
Insights
The lupus autoantibody 3E10 directly inhibits RAD51, a key protein in DNA repair, by binding its N-terminus. This discovery provides a molecular basis for developing 3E10 as a novel cancer therapy targeting homology-directed repair.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
Background:
- RAD51 is crucial for homology-directed repair (HDR) and a target for cancer therapy.
- Existing inhibitors are limited, and the mechanism of the autoantibody 3E10 was unclear.
Purpose of the Study:
- To elucidate the molecular mechanism by which 3E10 inhibits DNA repair.
- To determine if 3E10's anti-cancer effects are due to DNA binding or RAD51 inhibition.
Main Methods:
- Generating separation-of-function mutations in 3E10.
- Assessing 3E10 binding to RAD51 and DNA.
- Correlating mutation effects with HDR inhibition, cell penetration, and in silico modeling.
Main Results:
- 3E10 directly binds to the N-terminus of RAD51, sequestering it in the cytoplasm.
- Inhibition of HDR correlates with RAD51 binding, not DNA binding.
- Cell penetration is mediated by DNA binding.
Conclusions:
- 3E10 is a novel inhibitor of RAD51, suppressing HDR through direct binding.
- This mechanism explains 3E10's anti-cancer effects and guides its pre-clinical development.
More Related Videos
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
DNA Damage Can Stall the Cell Cycle

